These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33607245)

  • 21. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.
    Mukhopadhyay A; Curtin N; Plummer R; Edmondson RJ
    BJOG; 2011 Mar; 118(4):429-32. PubMed ID: 21244617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
    Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
    Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
    Moore KN; Pothuri B
    Cancer J; 2021 Nov-Dec 01; 27(6):432-440. PubMed ID: 34904806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.
    Pautier P; Motte-Rouge T; Lécuru F; Classe JM; Ferron G; Floquet A; Kurtz JE; Freyer G; Hardy-Bessard AC
    Bull Cancer; 2021 Dec; 108(9S1):S22-S32. PubMed ID: 34955159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PARP inhibition as frontline therapy in ovarian cancer.
    Moore KN; Pothuri B; Monk B; Coleman RL
    Clin Adv Hematol Oncol; 2020 Sep; 18(9):550-556. PubMed ID: 33006584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The systemic treatment of recurrent ovarian cancer revisited.
    Baert T; Ferrero A; Sehouli J; O'Donnell DM; González-Martín A; Joly F; van der Velden J; Blecharz P; Tan DSP; Querleu D; Colombo N; du Bois A; Ledermann JA
    Ann Oncol; 2021 Jun; 32(6):710-725. PubMed ID: 33675937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
    Gadducci A; Guerrieri ME
    Crit Rev Oncol Hematol; 2017 Jun; 114():153-165. PubMed ID: 28477743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
    Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
    Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
    Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
    Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
    Klotz DM; Wimberger P
    Arch Gynecol Obstet; 2020 Nov; 302(5):1087-1102. PubMed ID: 32833070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
    J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
    Konstantinopoulos PA; Spentzos D; Karlan BY; Taniguchi T; Fountzilas E; Francoeur N; Levine DA; Cannistra SA
    J Clin Oncol; 2010 Aug; 28(22):3555-61. PubMed ID: 20547991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
    Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
    Della Corte L; Foreste V; Di Filippo C; Giampaolino P; Bifulco G
    Expert Opin Investig Drugs; 2021 May; 30(5):543-554. PubMed ID: 33724122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmaceutical Management of Ovarian Cancer: Current Status.
    Markman M
    Drugs; 2019 Jul; 79(11):1231-1239. PubMed ID: 31267481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis.
    Lin Q; Liu W; Xu S; Shang H; Li J; Guo Y; Tong J
    BJOG; 2021 Feb; 128(3):485-493. PubMed ID: 32654312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rucaparib: a novel PARP inhibitor for
    Colombo I; Lheureux S; Oza AM
    Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
    Elsea D; Muston D; Fan L; Mihai A; Meng Y; Kasle A; Monberg M
    Target Oncol; 2023 Jul; 18(4):531-541. PubMed ID: 37233868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.